7,267 Moderna, Inc. $MRNA Shares Purchased by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 44.2% in the third quarter, HoldingsChannel.com reports. The firm owned 23,692 shares of the company’s stock after buying an additional 7,267 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Moderna were worth $4,562,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Merck & Co. Inc. acquired a new stake in Moderna during the 2nd quarter worth $161,642,545. Louisiana State Employees Retirement System purchased a new stake in Moderna in the first quarter valued at $899,000. Bank of New York Mellon Corp purchased a new stake in Moderna in the second quarter valued at $119,168,000. Contravisory Investment Management Inc. lifted its position in Moderna by 1,387.6% in the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after acquiring an additional 22,590 shares during the last quarter. Finally, TD Waterhouse Canada Inc. boosted its stake in Moderna by 2,042.6% in the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after acquiring an additional 69,203 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Moderna

In other news, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This trade represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is owned by company insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Detailed Phase 3 INTerpath-001 results showed positive recurrence-free survival and distant metastasis-free survival for intismeran autogene, Moderna’s individualized mRNA cancer vaccine used with Merck’s Keytruda. The results support the program’s potential to become a major non-COVID growth driver. Merck and Moderna INTerpath-001 Results
• Positive Sentiment: Moderna advanced its mRNA bird-flu vaccine into a late-stage trial, expanding its pipeline into pandemic influenza. The company also said it plans to reserve 20% of related manufacturing capacity for low- and middle-income countries if the vaccine is approved. Moderna Starts Late-Stage Bird Flu Trial
• Neutral Sentiment: Moderna’s addition to the Nasdaq-100 has increased institutional visibility and contributed to recent momentum, but the sharp run-up also left the stock vulnerable to profit-taking when new clinical information emerged. Moderna Nasdaq-100 Inclusion
• Negative Sentiment: Partial melanoma-vaccine data circulated online before Moderna’s scheduled ESMO presentation. Although the findings appeared clinically meaningful, investors viewed the leak as an information-quality and timing problem, while the lack of a fresh surprise raised “sell-the-news” concerns. Trading was temporarily halted because of volatility. Reuters Moderna Cancer Vaccine Data Report
• Negative Sentiment: TD Cowen raised its price target to $90 but maintained a Hold rating, leaving substantial downside relative to the stock’s recent trading level and reinforcing valuation concerns. TD Cowen Moderna Price Target
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to Moderna’s October 22 disclosure. The announcement does not establish wrongdoing, but it adds headline and legal risk following the abrupt decline. Moderna Securities Investigation

Moderna Stock Performance

MRNA stock opened at $202.63 on Friday. The company has a fifty day moving average price of $170.05 and a 200 day moving average price of $96.24. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $254.48. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the business earned ($2.13) EPS. Moderna’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research reports. CLSA raised Moderna to an “outperform” rating in a report on Friday, August 28th. Morgan Stanley boosted their target price on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Singular Research raised Moderna to a “hold” rating in a report on Wednesday, September 23rd. JPMorgan Chase & Co. upped their target price on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Finally, Barclays raised their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Seven research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $103.95.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.